Late morbidity and oncological outcome after radical hypofractionated radiotherapy in men with prostate cancer

BJU International

Volumn 106, Issue 10, 2010, Pages 1458-1462

  Di Staso, Mario ^a   Bonfili, Pierluigi ^a   Gravina, Giovanni L ^a,b   Di Genesio Pagliuca, Milena ^b   Franzese, Pietro ^a   Buonopane, Sergio ^a   Osti, Mattia F ^c   Valeriani, Maurizio ^c   Festuccia, Claudio ^b   Enrici, Riccardo Maurizi ^c   Tombolini, Vincenzo ^b  

^a SAN SALVATORE HOSPITAL   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

hormone therapy; hypofractionated radiotherapy; late morbidity; oncological outcome; prostate cancer

Indexed keywords

BICALUTAMIDE; LEUPRORELIN;

AGED; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RADIATION DOSE FRACTIONATION; RETROSPECTIVE STUDY; TOXICITY; TREATMENT FAILURE; UROGENITAL TRACT DISEASE;

AGED; DOSE FRACTIONATION; EPIDEMIOLOGIC METHODS; HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY; UROGENITAL SYSTEM;

EID: 78349242192     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09418.x     Document Type: Article

References (20)

1. McBride WH, Withers HR,. Biologic basis of radiation therapy. In, Perez CA, Brady LH, Halperin EC, Schmidt-Ullrich RK, eds Principles and Practice of Radiation Oncology. Philadelphia: Lippincott Williams & Wilkins; 2004: 96-136
2. Brenner DJ, Hall EJ,. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999; 43: 1095-101
3. Duchesne GM, Peters LJ,. What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose rate brachytherapy. Int J Radiat Oncol Biol Phys 1999; 44: 747-8
4. Brenner DJ, Martínez A, Edmundson GK, Mitchell C, Thames HD, Armour EP,. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002; 52: 6-13
5. King CR, Fowler JF,. A simple analytic derivation suggest that prostate cancer alpha/beta ratio is low. Int J Radiat Oncol Bio Phys 2001; 51: 213-4
6. Wang JZ, Guerrero M, Li XA,. How low is the alpha/beta ratio for prostate cancer? Int J Radiat Oncol Biol Phys 2003; 55: 194-203
7. Kupelian PA, Thakkar VV, Khuntia D, Reddy CA, Klein EA, Mahadevan A,. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: long term outcomes. Int J Radiat Oncol Biol Phys 2005; 63: 1463-8
8. Martin JM, Rosewall T, Bayley A, et al. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 2007; 69: 1084-9
9. Soete G, Arcangeli S, De Meerleer G, et al. Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: report on acute toxicity. Radiother Oncol 2006; 80: 78-81
10. Leborgne F, Fowler J,. Late outcomes following hypofractionated conformal radiotherapy vs. standard fractionation for localized prostate cancer: a nonrandomized contemporary comparison. Int J Radiat Oncol Biol Phys 2009; 74: 1441-6
11. McCammon R, Rusthoven KE, Kavanagh B, et al. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate-and high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2009; 75: 413-20
12. Tombolini V, Di Staso M, Bonfili P, et al. Subjective and objective measures of late genitourinary morbidity following hypofractionated radiotherapy in men with prostate cancer. Prostate Cancer Prostatic Dis 2010; 13: 34-8
13. Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J,. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007; 67: 1099-105
14. Kupelian PA, Reddy CA, Carlson TP, et al. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys 2002; 53: 904-12
15. Livsey JE, Cowan RA, Wylie JP, et al. Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis. Int J Radiat Oncol Biol Phys 2003; 57: 1254-9
16. Sobin LH, Wittekind CH, eds. The prostate. In TNM Classification of Malignant Tumors. New York: Wiley-Liss, 2002: 184-187
17. Diaz A, Roach M, Marquez C,. Indications for and the significance of seminal vesicles irradiation during 3D conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 1994; 30: 323-9
18. Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65: 965-74
19. Dische S, Saunders MI, Barrett A, Harvey A, Gibson D, Parmar M,. A randomized multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997; 44: 123-36
20. Horwitz EM, Thames HD, Kuban DA, et al. Definition of biochemical failure that best predicts clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol 2005; 173: 797-802